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Abstract: Ecological momentary assessment (EMA) and ecological momentary intervention (EMI)
are alternative approaches to retrospective self-reports and face-to-face treatments, and they make
it possible to repeatedly assess patients in naturalistic settings and extend psychological support
into real life. The increase in smartphone applications and the availability of low-cost wearable
biosensors have further improved the potential of EMA and EMI, which, however, have not yet been
applied in clinical practice. Here, we conducted a systematic review, using the Preferred Reporting
Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, to explore the state of the
art of technology-based EMA and EMI for major depressive disorder (MDD). A total of 33 articles
were included (EMA = 26; EMI = 7). First, we provide a detailed analysis of the included studies
from technical (sampling methods, duration, prompts), clinical (fields of application, adherence
rates, dropouts, intervention effectiveness), and technological (adopted devices) perspectives. Then,
we identify the advantages of using information and communications technologies (ICTs) to extend
the potential of these approaches to the understanding, assessment, and intervention in depression.
Furthermore, we point out the relevant issues that still need to be addressed within this field, and we
discuss how EMA and EMI could benefit from the use of sensors and biosensors, along with recent
advances in machine learning for affective modelling.
Keywords: major depressive disorder; ecological momentary assessment; ecological
momentary intervention
1. Introduction
Major depressive disorder (MDD) is a common debilitating psychiatric disease characterized by
mood disturbances, loss of interest and pleasure in daily activities, disturbed appetite and sleep, loss
of energy, and psychomotor retardation or agitation. According to the World Health Organization,
J. Clin. Med. 2019, 8, 465; doi:10.3390/jcm8040465 www.mdpi.com/journal/jcm
J. Clin. Med. 2019, 8, 465 2 of 26
depression is one of the leading causes of disease and disability in the world, annually affecting 4.4%
of the general adult population [1]. In addition to producing high costs for the public health system,
depression seriously impairs patients’ functioning, leading to increased mortality, high suicide rates,
exacerbated medical conditions, and high consumption of alcohol and illegal drugs [2–5].
As a result of the increased availability of smartphones and portable and wearable devices,
a growing body of research has begun to explore new digital technologies as potential tools to foster
assessments and interventions in clinical practice. More specifically, technology-based ecological
momentary assessment (EMA) and ecological momentary intervention (EMI) have been proposed as
alternative strategies to assess patients ecologically in naturalistic settings and deliver psychological
support in daily life.
1.1. Ecological Momentary Assessment
Traditional clinical assessments are based on retrospective self-reports in which patients are
asked to summarize their symptoms and affective experiences over the past few weeks. Nevertheless,
increasing evidence shows that these tools are not able to capture MDD dynamics, such as symptom
fluctuations or mood shifts over time [6,7]. Likewise, self-reports are affected by recall bias. In other
words, depressed patients have been found to alter the content of past experiences when asked to
retrieve them retrospectively [8,9], judging symptoms as more severe [10] or increasing the elaboration
of negative information [11].
EMA emerged as an alternative assessment strategy to better grasp affective and behavioural
dynamics in daily life [12–14]. Not surprisingly, a growing body of research has applied this approach
to exploring mood disorders [15,16]. On the one hand, the term “ecological” refers to the environment
where the data are collected. Behaviours, thoughts, and affect are repeatedly written down in real-world
contexts. On the other hand, the term “momentary” refers to the focus of the assessment, i.e., close in
time to the experience. The first studies to use this approach adopted paper-and-pencil daily diaries,
but the discomfort, low compliance, and low experimental control over backfilling made them not very
efficacious [14]. The exponential progress of information and communication technologies (ICTs) and
the increasing availability of smartphones offered novel opportunities to ecologically assess patients.
On the one hand, mobile technologies allow the shortcomings of traditional diaries to be overcome by
eliminating the need for manual data entry and by increasing control on backfilling, thus obtaining more
accurate data. On the other hand, all the necessary processes can be integrated in one tool, for instance,
a smartphone, thus decreasing intrusiveness and increasing users’ comfort, and providing a more
engaging and dynamic experience. During the day, indeed, patients are automatically prompted by the
device to fill in self-reports that are subsequently stored and safely sent to clinicians and/or researchers.
More recently, the potential of EMA was extended due to the integration of self-reports with data
gathered from embedded sensors and wearable biosensors, hence allowing for a multimodal approach.
Unobtrusive wearable biosensors can continuously monitor physiological parameters throughout the
day with high precision [17], whereas smartphone embedded sensors make it possible to indirectly
collect data about patients’ behaviours and habits, such as their social media use, physical activity,
or social interactions [18,19]. Overall, the integration of these tools has the potential to revolutionize
traditional assessments, leading to the exploration of new facets of MDD obtained in daily life contexts
that are often difficult to capture in laboratory settings.
1.2. Ecological Momentary Intervention
According to statistics, 70% of people suffering from mental disorders do not receive adequate
psychological treatment or reach complete clinical remission [20]. Affordances of technological
developments, as Kazdin and Blase suggested, may facilitate new solutions for disseminating
evidence-based psychotherapy [21].
The same “ecological” and “momentary” principles have been applied to the development of
innovative interventions (EMI) [22] that go beyond traditional clinical settings and extend the delivery
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of psychological support into real life [23]. EMI has the advantage of providing psychological support
directly on hand-held mobile technologies during the flow of daily experiences, in real-time settings,
and at specific time points in the day, without the need for face-to-face meetings with a clinician [24].
EMIs can be delivered both as stand-alone treatments or in combination with other treatments.
Moreover, similarly to EMAs, the use of data gathered from biosensors and embedded sensors along
with machine learning techniques can increase the customization of the proposed interventions [16,25].
1.3. Objectives
Recent studies have confirmed the feasibility of mobile health (mHealth) applications and patients’
interest in and adherence to these technologies, suggesting the great potential of this approach in the
clinical field [23,26]. Nevertheless, no systematic review has explored technology-based EMA and EMI
for MDD to date. Although two reviews focused on EMAs for mood disorders [15,16], most of the
included studies were based on paper-and-pencil daily diaries, and the target population included
adults and adolescents with bipolar disorder (BD) and borderline personality disorder (BPD).
Coinciding with our field of interest, the aim of this systematic review is to provide an overview of
the state of the art of technology-based EMA and EMI for MDD from both a clinical and technological
point of view. Our final objective is to show how and why clinical practice could benefit from the use
of these approaches. In doing so, we will describe the potential of new technologies in this field, and
we will discuss how EMAs and EMIs could be performed with sensors and biosensors along with
recent advances in machine learning for affective modelling.
2. Methods
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) criteria [27] were
followed. For the systematic review protocol, see [28].
2.1. Search Strategy
To collect relevant publications, a computer-based search was performed (March 2019).
We searched in two high-order databases, PubMed and Web of Science (Web of Knowledge), using the
following string: ((EMA) OR (“ecological momentary assessment”) OR (EMI) OR (“mobile health”)
OR (mhealth) OR (smartphone) OR (“ecological momentary intervention”) OR (ESM) OR (“experience
sampling method”) OR (“ambulatory assessment”) OR (“personal digital assistant”) OR (“ambulatory
monitoring”) OR (“real time data capture”) OR (“real time monitoring”) OR (“real time interventions”)
OR (“electronic diary”) OR (“repeated observations”) OR (“diary data”) OR (“time series”)) AND
((“affective disorder”) OR (“mood disorder”) OR (depress*) OR (depression) OR (MDD) OR (“major
depressive disorder”) OR (“major depression”) OR (“unipolar depression”) OR (“affective symptoms”).
This search produced a total of 4993 articles. After eliminating duplicate papers, we made a first
selection by reading titles and abstracts, and 401 articles were retrieved. We finally selected publications
by applying the selection criteria described in the following paragraph, obtaining 40 papers.
Three individual researchers (D.C., J.F.-Á., and M.S.) performed the search for publications in the
English language. More details are provided in Table 1 and in the flow diagram (Figure 1), in order to
make this search replicable in the future.
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Table 1. Detailed search strategy.
Process Results
PubMed/Medline 2758
Web of Science 2235
Total 4993
Not duplicated 3613
Excluded (after reading title and abstract) 3212
Retrieved 401
Excluded (after applying inclusion criteria) 361
Excluded (missing experimental data) 0
Final included articles 40
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intervention or combined with other types of treatment. We also included EMI that collected data from
wearable biosensors or device-embedded sensors. Because providing continuous feedback to patients
has been shown to be a valuable therapeutic procedure [29], we also included studies that adopted
EMA-based feedback as a therapeutic tool for clinically depressed patients.
2.3. Quality Assessment and Data Abstraction
To control for the risk of bias, PRISMA recommendations for systematic literature analysis were
followed. Studies were independently selected by three different authors (D.C., M.S., and J.F.-Á.), who
first analysed titles and abstracts and subsequently selected the full papers that met the inclusion
criteria, resolving disagreements through consensus. For what concerns the EMA included studies,
the main aim was to provide a perspective of clinical, technical, and technological issues related to
this approach: In other words, we were interested in EMA as a clinical and experimental tool to be
used in the psychological field, regardless of the study design or variables of outcome (Colombo et al.,
2018). No risk of bias assessment was therefore performed. Differently, risk of bias of EMI studies was
assessed by two independent reviewers (D.C and J.F.-Á.). As both randomized and non-randomized
controlled trials were included, quality assessment was assessed with the Downs and Black quality
index [30].
The data extracted from each study were as follows: Author(s), sample(s), variable(s), device(s),
sensor(s), duration, prompt(s) per day, sampling schema, primary outcome(s) for the selected studies
on EMA (Table 2); and author(s), name of the intervention, sample(s), content of the intervention,
duration, device(s), sensor(s), and primary outcome(s) for the studies proposing an EMI (Table 3).
3. Results
3.1. Ecological Momentary Assessment in MDD
After applying the inclusion criteria, 32 studies were retrieved that investigated and assessed
MDD through a technology-based EMA.
A synthesis of the results is provided in Table 2.
3.1.1. Electronic Devices and Use of Sensors
Most of the selected studies administered daily self-reports either through a personal digital
assistant (PDA) or a smartphone. Only three studies adopted different technological solutions
that allowed them to collect both self-reports and data gathered from sensors and biosensors.
Conrad et al. [31] used the LifeShirt System (Vivometrics, Inc., Ventura, CA, USA), a comfortable
garment with integrated biosensors that can continuously monitor various cardiopulmonary parameters,
including heart rate (HR), respiration, and posture. With an embedded hand-held computer, patients
can also complete self-reports following daily beep signals. In another study, Kim and colleagues
adopted ECOLOG [32], a watch-type computer characterized by an 8-direction joystick and an
integrated actimetry sensor. Via a beep signal, the wristwatch prompts patients to complete momentary
assessments directly on the watch screen. Similarly, a compact wrist–worn electronic diary was used
by Littlewood et al. to collect both self-reports and sleep/wake cycles with an embedded actimetry
sensor [33].
Although a growing number of studies analyse data from embedded-sensors and biosensors in
research on mental health disorders [34], their use in association with EMA has been low in the field
of MDD. Among our selected studies, only seven of the 32 studies collected physiological measures
in addition to self-reports. Conrad and colleagues collected cardiac and respiratory measures as
indices of vagal activity, along with physical activity measured through an embedded actimetry
sensor [31], whereas Ottaviani and colleagues collected ambulatory HR [35]. The remaining five
articles investigated the association of depressive symptoms with sleep/wake cycles [32,33,36] and
physical activity [37,38] using actimetry sensors.
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Table 2. More detailed information about the selected Ecological Momentary Assessment studies.
Authors Sample Variables Device(s) Duration Prompts PerDay
Sampling
Schema Compliance Sensor(s) Primary Outcome(s)
Recall bias
[8] MDD (n = 26), andHCG (n = 25) Affect Palm Tungsten E2 7 days 8 Semi-randomized 89% No
Both depressed and non-depressed
participants overestimate the retrospective
recall of PA and NA. Depressed patients are
more inaccurate in recalling NA.







29/30 days 3 Randomized 78% No
Even if strongly correlated, the PHQ-9 scores
collected through the mobile application are
significantly higher than those obtained














High rates of acceptance and compliance are
observed among both samples. Participants
show a practice effect, i.e., faster responses
over the course of the study.






14 days 1 Selected bythe patient
Not
specified No
Self-reported ratings of improvement at day 7
predict response to the treatment.














Baseline depression scores evaluated with
HAM-D are associated with scores of PHQ-9,
VAS for depression and anxiety symptoms






MDD (n = 32), mD
















In the control sample, daily activities are
negatively associated with cortisol levels. This




[43] MDD (n = 37), and
HCG (n = 36)
Sleep patterns; social











Depressed patients show lower cortisol
awakening response, lower sleep quality, and
more negative social interactions.1
(self-report)





















Cortisol level and HRV do not differ between
the two groups. Interestingly, NA is








Palm Tungsten E2 2 consecutive days 10 Semi-randomized 94% No
Rumination and low mood are associated
with increased activation of the HPAA. In
remitted patients, HPAA is less responsive to
subtle emotional events.













Compared to healthy participants, depressed
patients report higher cortisol levels, higher
α-amylase levels, and a greater ratio of
α-amylase over cortisol. This latter
association, however, disappears when
correction for lifestyle factors is applied.





PA and NA are bidirectionally associated with
cortisol levels. Nevertheless, the direction,
sign, and timing of this association show great
variability among subjects.
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Table 2. Cont.
Authors Sample Variables Device(s) Duration Prompts PerDay
Sampling




MDD (n = 35), mD
(n = 25), and HCG
(n = 36)
Positive and negative
affects PDA 3 days 10 Semi-randomized 65% No
Sleep quality predicts lower PA, but not NA.
Low PA is associated with poor subjective
sleep quality and self-reported daily
dysfunction.




Palm Pilot Zire 22 3 days 10 Semi-randomized 65% No
In the non-clinical sample, sleep disturbances
are associated with enhanced NA in response
to negative events. Considering depressed
patients, sleep disturbances negatively
influence the emotional reactivity to both
neutral and negative events.
[48] MDD (n = 27), andHCG (n = 27)
PA and NA, sleep
quality; tiredness;
rumination





Sleep quality directly influences PA and NA
experienced during the following day, but not
vice versa. Tiredness is a mediator.
[49] MDD (n = 14) and HCG(n = 15)
PA; NA; fatigue; sleep;
activities; cognition;
melatonin





Melatonin is associated with changes in affect
and fatigue. However, changes in affect and
fatigue are also predictors of melatonin levels.
Individuals that do not show this association
report higher depression severity and worse
sleep quality.









Sleep duration affects next-day physical
activity. Depression does not moderate this
association.








7 days 6 Semi-randomized 89% Accelerometer
Poor sleep quality, both objectively and
subjectively evaluated, is associated with
higher next-day suicide ideations. Suicide








Palm Pilot Zire 22 7 days 8 Randomized 75% No
Both samples show higher PA following
physical activity. More specifically, depressed
patients show a significantly higher increase in
experienced PA levels after physical activity.












Depressive mood is associated with increased
intermittency of locomotor activity.












Despite the observation of large
interindividual differences, results show a
positive effect of physical activity on PA in all
participants.
Rumination










Lower activation of bilateral PFC predicts
higher rates of rumination, whereas higher
levels of self-esteem are associated with lower
right PFC activity.















Depressed participants show higher rates of
perseverative cognition, which are associated
with lower HRV.
[52]
MDD (n = 38), GAD
(n = 36), MDD with
GAD comorbidity (n =
38), and HCG (n = 33)
Events stressfulness;
rumination Palm Pilot Zire 22 7 days 8 Randomized 72% No
MDD and GAD participants show the same
level of rumination, which is even more
severe in comorbid cases. Higher rates of
rumination are predictive of worse affect,
more maladaptive behaviours, and more
severe symptoms.
[53]
MDD (n = 16), GAD (n
= 15), MDD with GAD
comorbidity (n = 20),




Palm Pilot Zire 22 6 to7 days 8 Semi-randomized 65% No
Levels of rumination among all the clinical
samples are higher in response to significant
events. Decreased PA and increased NA are
associated with higher momentary
rumination.
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Table 2. Cont.
Authors Sample Variables Device(s) Duration Prompts PerDay
Sampling
Schema Compliance Sensor(s) Primary Outcome(s)
Emotional
reaction




“Revo” computer 7 days 5 Randomized 90% No
Past episodes of depression are likely to
increase the vulnerability to stressful events,
especially in male participants.
[55]
MDD (n = 35), mD
(n = 26), and HCG
(n = 38)
Context; mood;




Palm Pilot Zire 22
3 non-consecutive
days (over a
period of 5 days)
10 Semi-randomized 65% No
Both MDD and mD patients show lower
levels of positive affect and rate events as
more stressful and unpleasant than the control
group. Furthermore, they show a higher
reduction in negative feelings after positive
events.
[50] MDD (n = 53), andHCG (n = 53)
Affect; significant
events Palm Pilot Zire 22 7/8 days 8 Randomized 78% No
Results point out greater emotional instability
with respect to NA in depressed patients. No
differences are observed in terms of reactivity,
inertia, and instability in PA.
[56]
MDD (n = 21) and
MDD with BPD







7 days 5 Randomized 94% No
Comorbidity with BPD does not imply major
affective instability, but it is associated with
lower subjective perception of affective
reactivity.
[57] Remitted MDD (n = 10)and HCG (n = 11)












In both samples, higher levels of visual
imagery-based processing are associated with
higher levels of PA and better mood,
regardless of the valence of the imagery
content. Elevated levels of visual
imagery-based processing are not associated
with daily affective reactivity.
[58] MDD (n = 51), and BPD(n = 80)
PA, NA, fear; hostility;
sadness; interpersonal
events
Palm Pilot Zire 31 28 days 6 Semi-randomized 86% No
Rejection and disagreement increase NA
(especially hostility and sadness) both at a
momentary and daily level, regardless of the
diagnosis. The association between
rejection/disagreement and hostility is
stronger in BPD patients.




Palm Pilot Zire 22 30 days 3 Randomized 73% No
High levels of sadness and arousal are
predictive of gambling desire, regardless of
the diagnosis. Depressed individuals are
likely to gamble to increase PA or for social
reasons.






Web-based survey 30 days 4 Notspecified
Not
specified No
Using a person-by-person approach, results
show that moment-to-moment
symptomatology is mainly driven by positive
mood, hopelessness, anger, and irritability,
but not depressed mood, anhedonia, or worry.
MDD: major depressive disorder; mD: minor depression; HCG: healthy control group; BDP: borderline personality disorder; GAD: generalized anxiety disorders; PDA: personal
digital assistant; DD: dysthymic disorder; PFC: prefrontal cortex; PA: positive affect; NA: negative affect; HRV: heart rate variability; PHQ-9: Patient Health Questionnaire-9;
QUID-SR: Quick Inventory of Depressive Symptomatology—Self Report; HADS-A: Hospital Anxiety and Depression Scale; PANAS: Positive and Negative Affect Schedule; HPAA:
hypothalamic-pituitary-adrenal axis.
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Table 3. More detailed information about the selected Ecological Momentary Intervention studies.
Authors Name Sample Intervention Duration Prompts SamplingSchema Sensor(s) Primary Outcome(s)
[61] Mobylize! MDD (n = 7), withdifferent comorbidities
Mobylize! is a context-aware system,
composed of three main elements: (1) A
mobile application for the collection of
self-reports; (2) a website with feedback and
theoretical lessons; (3) periodic contacts
with trained coaches







models did not reach high levels of
accuracy, especially for mood.
[62] PsyMate




condition (n = 36), control
condition (n = 33)
Daily assessment of self-reports and weekly
EMA-derived feedback through face-to-face
sessions
3 days per week,
for 6 weeks 10/day Semi-randomized No
The use of EMA-derived feedback




were also maintained over time.
[63] PsyMate




condition (n = 36), control
condition (n = 33)
Daily assessment of self-reports and weekly
EMA-derived feedback through face-to-face
sessions
3 days per week,
for 6 weeks 10/day Semi-randomized No
The use of Psymate as a technique
of self-monitoring could improve
patients’ feelings of empowerment.
[64] PsyMate




condition (n = 36), control
condition (n = 33)
Daily assessment of self-reports and weekly
EMA-derived feedback through face-to-face
sessions
3 days per week,
for 6 weeks 10/day Semi-randomized No
Face-to-face EMA-derived
feedback sessions did not increase
the rate of PA experienced during
or shortly after the intervention.
[65] Medlink MDD (n = 8)
Medlink is a mobile application delivering
psychological support to MDD patients.
The application provides users with: (1)
psychoeducation; (2) weekly symptom
assessment; (3) medication adherence
monitoring; (4) monthly communication
with a professional based on the previous
points
4 weeks 1/week Not specified No




Depression severity of participants
significantly decreased over the
course of the experiment.
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Table 3. Cont.
Authors Name Sample Intervention Duration Prompts SamplingSchema Sensor(s) Primary Outcome(s)
[66] Help4Mood
MDD (n = 28):
Experimental condition
(n = 14) and control
condition (n = 14)
Web platform providing daily assessment of
symptoms, self-monitoring, and tailored
activities. The delivered content is created










Only half of the participants used
Help4Mood regularly. Significant
changes in depressive symptoms









condition (n = 36), control
condition (n = 33)
Daily assessment of self-reports and weekly
EMA-derived feedback through face-to-face
sessions
3 days per week,
for 6 weeks 10/day Semi-randomized No









condition (n = 30), control
condition (n = 24)
Daily assessment of self-reports and weekly
EMA-derived feedback through face-to-face
sessions
3 days per week,
for 6 weeks 10/day Semi-randomized No
The use of a self-monitoring EMA
improves negative emotion
differentiation.
MDD: major depressive disorder; PA: positive affect; CESD-VAS-VA: brief visual analogue scale version of the Center of Epidemiological Studies Depression. Scale; PHQ-9: Patient
Health Questionnaire.
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3.1.2. Sampling Methods
Currently, different EMA designs can be used to define prompt scheduling, depending on
the main purpose of the study. It is possible to prompt participants using fixed time periods
or randomized/semi-randomized samplings (time-based sampling). Alternatively, participants
can be asked to personally fill in the assessment after the occurrence of a specific behaviour or
event (event-based sampling). Whereas time-based samplings depend on a signal emitted by the
device (signal-contingent), event-based samplings are not preceded by a prompt (event-contingent).
Signal-contingent schemas are useful when repeated measures are needed to obtain a representative
value of a variable or when the objective is to capture dynamic variables (e.g., mood), whereas
event-contingent schemas are more likely to be adopted when the main focus is on a specific behaviour
that occurs randomly or less frequently during the day (e.g., smoking a cigarette). Regarding our
selected studies, none of them adopted event-based sampling. Most of the studies collected data
using randomized or semi-randomized schemas, whereas nine studies prompted participants to note
information at fixed time points during the day. This latter approach was adopted especially by the
studies that investigated the association between cortisol or melatonin and depression, i.e., when the
assessed variable required greater temporal precision and accuracy.
The duration of the data collection showed great variability. Some studies collected self-reports
for a brief time period (less than 3 days); this choice was especially observed in the field of cortisol and
sleep pattern research. Other studies required longer periods of assessment, where participants were
involved for one or two months. This was especially true for studies investigating physical activity
and its association with depressive symptoms. The same high variability was observed in the number
of prompts, which varied from 1 to 20 prompts per day.
3.1.3. Compliance and Dropout Rates
With the term “compliance”, we refer to the percentage of answered prompts. A few studies did
not report this information [35,40–42,51,57,60]. However, the majority clearly addressed this issue.
Sixteen studies reported compliance rates higher than 85%, five studies showed rates between 84%
and 70%, and four studies collected 65% of the total possible answers. Patient dropout was related to
diagnosis change, subjective burden, technical problems, incomplete data, retrospective completion of
the electronic diary, missed prompts, worsening of symptoms, or non-attendance at follow-up sessions.
To prevent backfilling, different solutions were adopted. In most of the studies, participants
could complete self-reports for a fixed time period after the prompt, ranging from a few minutes to a
maximum of one hour. To increase compliance, two studies also gave participants the possibility of
postponing prompts.
3.1.4. Contribution of EMA to the Study of MDD
As Table 4 shows, so far EMA has been applied to seven different fields. In the following paragraph,
we will provide an overview of EMA’s contribution to the understanding and assessment of MDD.
Table 4. Fields of application of EMAs for Major Depressive Disorder.
Field of Application Retrieved Articles Aim Advantages
Recall bias [8,26] Experimental
No retrospective bias; control over
backfilling; repeated momentary
measurements.
Symptoms monitoring [39–41] Clinical
Continuous monitoring (symptoms
assessment, treatment progress);
real-time feedback to clinicians (e.g.,
crisis plan) and users (e.g., patterns
visualization).
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Table 4. Cont.
Field of Application Retrieved Articles Aim Advantages
Cortisol dysregulation [31,36,42–45] Experimental




Sleep patterns [33,38,46–49] Experimental
Control over backfilling; no
retrospective bias; integration of
self-reports with passive data
supplied by sensors and biosensors.
Physical activity [32,37,50] Experimental
Role of contextual variables;
integration of self-reports with




Rumination [35,51–53] Experimental Role of contextual variables;rumination deployment across time.
Affect and emotional
reactivity [50,54–60], Experimental
Role of contextual variables;
temporal deployment of affect and
emotional reactivity.
Recall Bias
Increasing evidence shows that memories often have inaccurate and imprecise content due to
recall bias. In the case of EMAs, two studies were carried out to investigate this bias, comparing EMA
daily data to retrospective assessments. Ben-Zeev and colleagues compared positive (PA) and negative
(NA) affect collected through an EMA to scores obtained by means of traditional paper-and-pencil
retrospective questionnaires [8]. When retrospectively recalled, both PA and NA were overestimated,
regardless of the diagnosis. Interestingly, the control group was more likely to exaggerate the retrieval
of PA rather than NA, but this trend was not observed in depressed patients. By contrast, Torous
and colleagues developed a smartphone application to administer randomized subsets of items taken
from the Patient Health Questionnaire (PHQ-9) [69], compared to the traditional paper-based PHQ-9.
Symptoms were evaluated as more severe in daily EMA evaluations, compared to the retrospective
PHQ-9 assessment. According to the authors, this discrepancy could be due to different factors, such
as recall bias or stigma.
Symptom Monitoring
Unexpectedly, we could only retrieve three studies within this research field, i.e., studies that
actually applied EMA to monitor clinically depressed patients. Husky and colleagues investigated the
acceptability of a three-days computerized ambulatory monitoring on MDD and BD patients, showing
encouraging compliance and acceptance rates among both samples. Practice effects were observed
(faster response time over the course of the study), thus suggesting the importance of considering
the potential effects of EMA duration on self-reports [39]. Schaffer et al. developed a system called
“Mental Health Telemetry” to monitor symptoms of patients receiving pharmacological treatment [40].
According to the results, a reduction in depressive symptoms was already observable one day after
beginning the treatment, and symptoms on day 7 were predictive of treatment outcome. Similarly,
iHOPE is a smartphone application for the daily monitoring of depressive symptoms and sleep
patterns [41]. EMA assessments of depression, sleep quality, and anxiety were highly associated with
the Hamilton Depression Rating Scale (HAM-D), administered at baseline. Nevertheless, application
use decreased significantly over the weeks, from 3.4 days per week to 0.4 days per week after 8 weeks,
highlighting the important issue of compliance in EMA assessments.
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Cortisol Secretion
Stetler and colleagues investigated the associations among cortisol and sleep patterns, social
interactions [43], and daily activities [42]. Not only were cortisol levels after awakening different in
depressed and healthy participants, but the impact of psychosocial variables on cortisol secretion was
also dissimilar. Consistently, the Hypothalamic–pituitary–adrenal (HPA) axis of depressed patients
was no longer able to respond to the timing of the sleep-wake cycle, daily routines, and external social
experiences. One study explored the impact of cortisol on affect, showing a bidirectional association
between PA and NA and daily cortisol levels [45]. Nevertheless, high variability was observed
among participants regarding the timing, direction, and sign of this association. For instance, NA was
positively associated with cortisol 50% of the time, while the association between cortisol and PA was
almost always negative. Booij et al. identified higher cortisol and α-amylase levels among depressed
individuals [36]. Similarly, when applying individual correction for lifestyle factors, the association of
depression to cortisol and the ratio of α-amylase over cortisol was no longer significant, suggesting
that generalization from groups does not always reflect the single individual. Nevertheless, Conrad
and colleagues could not find cortisol differences between depressed and non-depressed participants.
Interestingly, a negative correlation between NA and heart rate variability (HRV) was observed only in
the control group, suggesting that constant NA may alter the normal interaction between affectivity
and the autonomic nervous system [31].
Finally, interesting outcomes were also observed among remitted MDD patients [44]. Despite
remission, patients showed reduced cortisol levels throughout the day and a different interaction
between affect and cortisol, thus suggesting a reduction in the HPA axis’ responsiveness as a potential
marker of recurrent depression.
Sleep Patterns
According to our search, six studies adopted an EMA to explore sleep disturbances in depression.
Through the daily administration of morning self-reports about sleep patterns, O’Leary et al. found
that depression was associated with lower perceived sleep quality, which in turn affected negative
emotional reactivity to both neutral and unpleasant events during the day [47]. However, in healthy
participants, sleep disturbances only affected emotional reactivity to unpleasant events. In other words,
depression could be a factor affecting the relationship between sleep quality and emotional reactivity.
Similarly, two studies analysed the influence of sleep quality on daily affect [46,48]. As expected, higher
sleep quality was associated with higher PA in both healthy and depressed participants. Surprisingly,
there was no evidence of the moderating role of depression in the association between sleep and affect.
Nevertheless, sleep quality affected daily mood, but not vice versa, because higher sleep quality was
associated with increased PA and decreased NA the following day. This association did not differ
between depressed and healthy participants. Similarly, sleep duration was found to affect next-day
physical activity, but again, no difference between depressed and non-depressed individuals was
observed [38]. An EMA was finally adopted to investigate the association between sleep patterns
and suicide ideation in a sample of depressed patients [33]. Poor sleep quality, both at subjective and
objective levels, was associated with increased suicide ideations the following day. However, suicidal
thoughts did not predict sleep patterns the following night.
Bouwmans and colleagues also collected repeated saliva samples to analyse the association
of depression with melatonin, an important hormone related to sleep onset [49]. A bidirectional
relationship between affect and fatigue, and melatonin was pointed out: Melatonin is associated
with changes in affect and fatigue; however, affect and fatigue are also predictors of melatonin levels.
Participants that did not show this association were likely to report higher rates of depression, worse
sleep quality, and lower energy expenditure.
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Physical Activity
In order to analyse the effect of self-initiated physical activity on mood, clinically depressed
patients were asked to report their daily physical activity [50]. Both healthy and depressed participants
showed higher levels of PA following physical activity, but no decrease in NA. Notably, the increase
in PA after physical exercise was greater in depressed patients, which is consistent with the ample
evidence supporting behavioural activation in general, and physical activity in particular, for the
treatment of depression. Confirming these results, another study found that physical activity was
associated with subsequent increased PA, regardless of the diagnosis [37]. However, the analysis also
revealed high subjective variability in the association between physical activity and mood in terms of
strength, direction, and temporal aspects. Finally, Kim and colleagues developed a statistical model
with cross validity that identified a significant association between higher intermittency of locomotor
activity and worse mood ratings [32], suggesting the possibility of predicting patients’ moods through
the analysis of momentary locomotor patterns. According to their model, a worsening of depressive
mood was associated with increased intermittency of locomotor activity.
Rumination
Ruscio and colleagues investigated the relationship between stressful events and rumination
in MDD and GAD patients [52]. Both clinical samples showed higher levels of rumination in
response to stressful situations, which were further worsened by symptom severity and extensive
comorbidity. In addition, rumination significantly mediated the impact of stress on symptoms and
affect; that is, higher rumination after a stressful event predicted greater NA and more maladaptive
behaviours. Putman and colleagues investigated rumination and self-esteem through the assessment
of resting baseline PFC alpha activity, along with the momentary assessment of affect and depressive
symptoms, in a sample of clinically depressed individuals [51]. Rumination was found to be associated
with an increased alpha signal in the bilateral prefrontal cortex (i.e., decreased neural activation),
whereas an increased alpha signal in the right prefrontal cortex was positively correlated with higher
self-esteem ratings. One study investigated perseverative thoughts (i.e., depressive rumination, worry,
and reactive rumination) in relation to mind wandering [35]. Participants were instructed to complete
a smartphone diary every 30 min for one day, and these self-reports were integrated with continuous
HR monitoring. Confirming the hypothesis that mind wandering is not a maladaptive behaviour per
se, only perseverative cognition was associated with health risk factors, such as lower HRV, worse
mood, and higher interference in daily functioning. Finally, one study examined the dynamics of worry
and rumination in daily life [53]. Contrary to the hypothesis, levels of worry were not significantly
associated with the occurrence of significant events, whereas rumination was significantly higher in
response to these circumstances. Compared to the control group, clinically depressed individuals
showed decreased PA and increased NA as a consequence of high rumination levels.
Affect and Emotional Reactivity
Thompson and colleagues investigated emotional reactivity, emotional inertia, and emotional
instability in depressed patients [50]. Compared to healthy participants, clinically depressed patients
showed higher NA instability, whereas no differences in PA instability were observed. Both samples
reported increased NA after a negative event; however, depressed patients showed a greater decrease
in NA and increase in PA after a positive event. These results were confirmed by another study that
showed a greater reduction in NA following positive events in depressed individuals [55]. When
considering BPD comorbidity, depressed patients were found to be less emotionally influenced by
events, and to perceive themselves as less emotionally reactive [56]. Other factors that affect emotional
reactivity are gender and past depression [54]. In one study, women and remitted patients evaluated
daily events as more negative than men, and they showed worse mood and higher emotional reactivity
in response to daily stressors. Finally, a smartphone application was developed to assess visual
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mental imagery and its impact on mood and affective reactivity in healthy people and remitted MDD
patients [57]. Participants were asked to focus on their mental representations, i.e., what they had in
mind, eight times per day. Imagery-based processing was associated with better mood, regardless of
the valence of the mental representation. This pattern was similar in healthy and depressed participants.
However, no association between mental imagery and affective reactivity was observed.
Regarding daily affect, one study explored the impact of gambling desire on mood in a sample of
depressed individuals [59]. Higher levels of sadness and arousal were associated with higher rates of
gambling desire. Consistently, depressed participants were also likely to perform gambling behaviours
to increase their current PA levels. However, momentary affect did not predict actual gambling
behaviours. An EMA was also used to investigate the influence of social rejection and disagreement on
daily affect in MDD and BPD patients [58]. As expected, momentary and daily negative interpersonal
events triggered higher NA (fear, hostility, and sadness) in both groups. High levels of hostility
predicted rejection and disagreements, whereas sadness was only a predictor of social rejection. The
aforementioned relationships were stronger in BPD patients than in depressed participants.
Finally, one study investigated the topology and temporal dynamics of depression and
anxiety symptoms using contemporaneous and temporal network models [60]. Positive (positive,
content, enthusiastic, energetic) and negative (down) mood were the most representative variables
of patients’ core symptoms. While “worried” and “down” did not show temporal influence,
“positive mood”, “hopelessness”, “anger”, and “irritability” were the strongest drivers of
moment-to-moment symptomatology.
3.2. Ecological Momentary Intervention in MDD
The selection process resulted in eight studies that administered an EMI to clinically depressed
patients. In all, four different interventions were identified: Psymate, Mobylize, Hel4Mood,
and Medlink.
3.2.1. General Overview of the Interventions
Psymate is a PDA-based EMA for symptom monitoring that aims to increase awareness about
depression and the dynamics that characterize this disorder [62–64,67,68]. Psymate allows patients to
record daily symptoms and affect. Based on these daily assessments, patients meet a clinician weekly
and receive graphical feedback on the association between PA levels and daily life activities, events, or
social interactions, as well as on the association between PA changes and the number of depressive
complaints. In this way, patients have the chance to reflect on their affective state and the relationship
between symptoms and contextual variables with a professional. According to Heron’s definition,
“the key feature of all EMIs is that the treatment is provided to people during their everyday lives
(i.e., in real time) and settings (i.e., real world)” [22]. Therefore, Psymate does not meet all the criteria
for an EMI, as EMA-feedbacks are provided during weekly face-to-face sessions. However, we decided
to include this intervention because we think it provides important insights about the potential of
self-monitoring EMA as a therapeutic tool.
Likewise, Mobylize! constitutes an ecological intervention composed of a mobile application, an
interactive website, and a system for email/telephone support [61]. The most innovative aspect of
this application is the integration of self-reports with data from smartphone sensors. Mobylize! is
provided with a context-aware system. Thanks to a machine learning algorithm, the application can
predict the state of the patient (mood, emotions, cognitive/motivational states, activities, environmental
context, and social context). Specifically, the system works in three different phases: (1) Data collection,
during which 38 sensors collect sensor information; (2) learners, during which prompted self-reports
are matched and paired with simultaneously labelled state data to develop predictive models; and (3)
action components, a continuous process that analyses sensor data in order to update previous
predictive models without the direct input of the user. Mobylize! is designed to prompt patients to
assess mood, intensity of emotions, fatigue, pleasure, accomplishment, concentration, engagement,
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perceived control, location, and interactions five or more times a day. To accommodate new data,
every new self-report is subsequently associated with the generation and modification of previous
models. Thanks to this complex system, the mobile application sends tailored feedback to participants.
Through the website, users can graphically visualize self-report patterns, read theoretical lessons,
and use interactive tools, such as tailored plans and calendars, for monitoring daily activities. Lastly,
a trained clinician contacts users periodically by phone or email to provide technical support, reinforce
adherence, and enhance motivation.
Help4Mood is a web-platform to self-monitor daily symptoms, mood, activities, and thoughts [66].
Based on a Cognitive Behavioural Therapy (CBT) approach, Help4Mood helps patients to reflect on
the emotional and cognitive patterns related to depression. In addition to collecting daily self-reports,
the application receives data from an actimetry sensor and acoustic analysis of speech. The innovative
aspect of Help4Mood is the use of a virtual agent, completely customizable in terms of voice, clothing
style, sex, and language, that communicates with users to provide tailored exercises and activities and
guide them through the daily questionnaires. The application also has an emergency section called the
“crisis plan”: As soon as symptom worsening is detected, the application prompts users to contact a
professional or a relative.
Finally, Medlink is a mobile application to support and monitor MDD patients taking
antidepressant medication [65]. The main purpose of the app is to address the failure points that usually
occur between professionals and newly diagnosed patients. On the one hand, the application provides
users with weekly psychoeducation material and sends suggestions about medication management
and how to deal with depressive symptoms. On the other hand, it monitors patients’ treatment and
depressive symptoms. Every four weeks, personal communication with a professional is scheduled to
give patients monthly feedback about disease progression.
3.2.2. Effectiveness of the Intervention
Psymate was tested in a sample of 102 clinically depressed patients in a three-arm randomized
controlled trial [62–64,67] with an experimental condition (treatment as usual – TAU - and six-week
Psymate treatment, with weekly face-to-face feedback sessions), a pseudo-experimental condition
(TAU and Psymate without EMA face-to-face feedbacks), and a control condition (TAU). Three different
categories of weekly feedback were provided: (1) Positive affect, (2) positive affect in relation to events
appraised with an internal versus external locus of control, and (3) positive affect in relation to social
interactions. Results showed a significant reduction in depressive symptoms in the experimental
group that was maintained in the follow-up assessment. Participants in the pseudo-experimental
condition reported decreased depressive symptoms in the first weeks of the treatment, but this gain
was not maintained across the weeks. Notably, the use of Psymate was associated with increased
levels of perceived empowerment, regardless of the presence of weekly feedback, and with increased
experienced PA throughout the treatment. Decreased depressive symptoms were also associated with
increased positive daily behaviours. Finally, Widdershoven and colleagues observed a significant
improvement in negative emotions’ differentiation and a close-to-significance improvement in positive
emotions’ differentiation after 6-weeks of self-monitoring, regardless of EMA-derived feedbacks [68].
Mobylize! was tested in a small pilot study with a sample of 7 MMD patients [61]. According to the
results, the use of Mobylize! significantly reduced depressive symptoms, both on a self-rated measure
(PHQ-9) and a clinician-based evaluation (Quick Inventory of Depressive Symptomatology-Clinician
Rating, QUIDS-C), as well as anxiety symptoms, measured with the Generalized Anxiety Disorder
Scale (GAD-7). At the end of the treatment, participants were also less likely to meet MDD diagnostic
criteria. Nevertheless, the accuracy of the predictive model was low, especially for mood; higher
accuracy was achieved by models that predicted location, conversational state, and social interactions
(accuracy between 60% and 90%).
A randomized controlled trial was conducted to evaluate Help4Mood [66]. Twenty-eight depressed
patients were recruited and randomized into two treatment groups: Help4Mood and TAU. Outcome
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measures, which included the Beck Depression Inventory (BDI) and Quick Inventory of Depressive
Symptomatology—Self Report (QIDS-SR), indicated reduced symptoms in both samples. Nevertheless,
patients in the TAU group achieved greater clinical improvement compared to patients who used the
application. Notably, regular users were more likely to obtain greater clinical improvement compared
to users with low compliance.
Finally, a preliminary study tested the efficacy of Medlink with 8 MDD patients [65]. On the
one hand, medication monitoring showed promising outcomes. Patients reported taking 84% of their
medication, which is significantly higher than medication adherence rates reported in the literature.
On the other hand, depressive symptoms significantly decreased over the course of 4 weeks.
3.2.3. Compliance and Dropout Rates
Regarding Psymate, the number of answered prompts in both the experimental and
pseudo-experimental groups was 135.5 out of 180 (75.3%); participants completed 39.7 out of 50
pre-assessments (79.4%) and 23.7 out of 30 (79%) post-assessment observations. Moreover, 27 of the 33
participants (81.9%) allocated to the experimental group completed the intervention, whereas 32 out of
36 participants (88.89%) allocated to the pseudo-experimental group completed it.
Throughout the 8-week treatment with Mobylize, the mean number of log-ins to the mobile
application was 7.9 (approximately one per week), whereas the number of completed lessons on the
website was 4.8 out of 9 (53.3%). The number of answered prompts drastically decreased throughout
the treatment, from 15.3 in the first week to 4.8 in the last week, due to technical difficulties and
connectivity problems. Seven out of eight participants (87.5%) completed the intervention: The only
dropout was caused by technical problems with the smartphone.
Regarding Help4Mood, the authors indicated great variability in terms of time of use. Two
participants used the application for one or two days, whereas three participants used it between 3
and 7 days. The remaining six participants used it more than 10 times, approximately twice a week.
The mean use was 134 min. Eleven out of 13 (84.6%) participants completed the protocol and were
assessed for the follow-up. One participant withdrew due to worsening mood.
Finally, participants entered the Medlink application approximately 17.4 times during the 4 weeks
of data collection and answered 96% of the prompts. Seven out of nine users read the psychoeducation
lessons from the first and second week, whereas only half of them read the third and fourth lessons.
No dropouts were reported.
3.2.4. Participants’ Feedback and Satisfaction
Using Likert scales ranging from 1 to 7, participants found that Psymate was very simple to use
and provided clear instructions (verbal instructions = 6.6 ± 0.7; written instructions = 6.5 ± 1.0; Psymate
answers = 2.6 ± 1.5). The number of daily prompts and the time needed to complete assessments was
not stressful (number of beeps per day = 3.1 ± 1.6; time to answer = 2.5 ± 1.5). Finally, satisfaction
with its most important feature, i.e., receiving EMA-derived feedback, indicated that the feedback was
highly appreciated (usefulness of feedback = 6.2 ± 0.7) and considered valuable (feedback to improve
daily skills = 5.4 ± 1.1). However, participants would have appreciated receiving more specific and
practical advice related to the EMA-based feedback (3.2 ± 2.0).
Regarding Mobylize, satisfaction with the application was rated as 5.71 on a scale from 1 to 7.
Criticism was related to technical problems, such as loss of connectivity and subsequent failure to
receive prompts. Interestingly, 86% of the participants reported that the intervention was particularly
helpful for identifying NA triggers and avoiding distressing and maladaptive behaviours. Participants
also suggested lengthening the intervention and adding more activities, such as a blog to talk with
other users or a message service between patients and coaches.
Participants involved in the Help4Mood study were quite satisfied with the application. Most of
them would use it in everyday life and suggest it to other patients. The idea of a virtual agent to guide
participants in completing the assessments was appreciated; however, some participants perceived the
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agent as too cold, repetitive, and not sufficiently realistic. Among the limitations, patients reported
sometimes being bored by excessively long sessions. They would have appreciated receiving more
psychoeducational material and a more tailored experience, allowing them to access their preferred
materials and activities without restrictions.
Medlink’s usability was assessed using 4 items from the Usefulness, Satisfaction, and Ease of
Use Questionnaire (USE). On a scale from 1 to 7, participants reported encouraging scores for ease
of use (mean = 5.7 ± 1.1) and learnability (mean = 6.1 ± 1.5), but low scores for perceived usefulness
(mean = 4.6 ± 1.0) and satisfaction (mean = 4.8 ± 0.8). Furthermore, encouraging ratings were observed
for the weekly psychoeducation lessons (liking = 6.0± 1.1; ease of use = 6.6± 0.5; learnability = 6.6 ± 0.5;
and usefulness = 5.8 ± 1.7), which were also reported to be the most interesting and useful parts of the
application. Finally, feedback interviews showed neutral comments regarding daily self-reports, that
were perceived as not very useful; contrasting opinions were collected regarding feedback graphs.
4. Discussion
To date, the scientific literature has mostly been based on studies conducted in laboratory settings,
thus understudying the daily dynamics of psychopathology [70]. Therefore, unobtrusively monitoring
behavioural (i.e., sensors), physiological (i.e., biosensors), and cognitive/emotional (i.e., self-reports)
factors in ecological settings collected through portable and wearable devices can provide new
information about elusive psychological constructs that are usually defined by the complex dynamics
of contexts and variability. Accordingly, the research field could benefit from the use of novel
technologies to better explore MDD mechanisms and delineate new theoretical models based on
ecological observations.
Compared to paper and pencil daily diaries, the use of electronic devices, and especially
smartphones, could further increase the six EMA advantages identified by Ebner-Premier (Table 5) [16]:
(a) The automation of the entire process directly on a mobile device, such as a smartphone, can
provide greater control over backfilling and higher temporal precision in the administration, planning,
and randomization of prompts; (b) the use of ICTs can offer additional possibilities for multimodal
assessments, with data supplied by embedded sensors and wearable unobstructed biosensors that can
automatically be coordinated with the collection of self-reports; (c) the use of mobile devices reduces the
effort required of users in completing daily assessments and prevents errors by researchers and clinicians
due to manual data entry; (d) smartphones offer the possibility of providing real-time EMA-derived
feedback that can be an important therapeutic tool for patients’ self-monitoring, in addition to the
possibility of sending real-time alerts to clinicians in case of need. In this regard, smartphones have the
potential of becoming global low-cost tools that can also be adopted in the clinical field. Currently,
2.32 billion people in the world use smartphones, and it has been estimated that, by 2020, 70% of
the world’s population will own one [71]. The potential of these devices is also supported by the
evidence showing that people with serious mental and physical illnesses own and regularly use
smartphones [72] and are interested in using applications for their health [26].
As pointed out in this review, the widespread adoption of EMA for the investigation of depression
has led to novel insights into different aspects of the disease, including emotion reactivity, cortisol
patterns, or daily rumination. We discussed different sampling methods that can be used in EMA
protocols, showing that the signal-contingent design with prompt randomization or semi-randomization
is the most widely adopted option when dealing with variables, such as affect and symptom monitoring.
We also reported compliance and dropout rates, which showed encouraging results, with most of
the studies reporting more than 70% adherence. Nevertheless, the gap between clinical practice and
research is still quite wide, as revealed by the low number of studies that adopt this approach to assess
and monitor patients for clinical purposes or implement EMA in clinical settings. Accordingly, many
issues still need to be addressed. To date, no standard and validated sets of items have been developed
for EMA protocols, raising the problem of context validity. Moreover, further research should be
conducted to improve patients’ compliance and reduce dropout. Due to the intrinsic nature of the
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disease, depressed patients could be less likely to consistently complete daily assessments. In a previous
study, we observed that compliance was higher in EMA administered through a smartphone and when
patients were prompted less than 8 times a day [73]. However, a meta-analysis should be conducted to
more precisely identify the factors that improve adherence (see, for example, [74]), thus providing
some sort of guideline for the design of EMA. Indeed, we strongly believe that clinical practice could
benefit from the use of EMAs for several reasons. First, EMAs can be useful for diagnostic purposes.
Traditional diagnostic procedures usually involve a static moment in time, including semi-structured
interviews (e.g., Mini-International Neuropsychiatric Interview) complemented by self-report measures.
However, ample evidence shows the dynamic nature of affective states and mood [75]. Furthermore,
these dynamics greatly vary from person to person, reasons for which ideographic approaches may
shed light upon the structure of individual symptom dynamics [60]. Consequently, by means of
EMAs, a more accurate diagnostic process could be pursued. Likewise, the continuous monitoring
of patients’ symptoms would allow clinicians to monitor the efficacy of a treatment over time [76],
predict short-term mood changes [77], detect symptoms’ worsening in an early stage [78], and create
continuous communication between clinicians and patients. On the other hand, the use of daily mood
and symptom self-ratings could provide more ecological assessments, overcoming recall bias and
capturing the dynamics of human functioning in daily life that cannot be detected with traditional tools.
Table 5. Benefits of using EMA for mood dysregulation and mood disorders as described by
Ebner-Premier [16].
Advantages Implications




dynamic changes in symptoms.
3 Multimodal assessments
Contemporary analysis of behaviours,
physiological signals, and subjective
experiences.
4 Context-specific information Assessment of symptoms ascontext-dependent.
5 Interactive assessments Real-time customizable andinteractive feedback.
6 Generalizability Higher ecological validity andcollection of more representative data.
Our results also highlight the existence of a small number of EMIs for depression. In the current
literature, only four ecological interventions have been developed, and only two of them were tested
in a randomized-controlled trial (RCT). Our review showed promising results in terms of patient
satisfaction and clinical efficacy, further supporting the need for more efforts in this direction. However,
compliance rates were sometimes not encouraging, and a major challenge is to encourage regular use
of these technologies throughout the entire treatment process [79]. Accordingly, future research should
focus on the concept of users’ motivation and engagement, taking into consideration the adoption
of focus groups with patients during treatments, using mixed quantitative and qualitative designs
to obtain as much information as possible to guide future developments, and extending the effects
of gamification features on adherence and compliance [80]. In other words, greater attention should
be paid to the needs and characteristics of the target population. Considering feedback from users,
here, we were able to identify three EMI features that were highly appreciated: The possibility of
receiving visual feedback about daily assessments and, therefore, self-monitoring of daily patterns;
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the availability of psychoeducational material on depression and its mechanisms; and the opportunity
to have continuous or periodic communication with a trained clinician.
In this review, we found that most of the EMAs were based only on self-reports, whereas more
attempts to integrate this information with data gathered from sensors and biosensors were observed
for EMIs. Recent advances in sensor technologies have had an impact on applications for remote
health [81], such as postoperative recovery [82], treatment for chronic patients [83], and monitoring of
elderly individuals [84]. Consistently, the hierarchical sensing model proposed by Mohr highlights the
great revolution that new sensors and biosensors can bring to the field of mental health [85], making it
possible to collect raw sensor data (i.e., the lower level of the hierarchy) that can be converted into
“behavioural markers” through machine learning and data mining methods [18].
Smartphone sensors further increase the potentially collectable information, allowing the
reconstruction of people’s habits, sleep patterns, or social life by using embedded sensors, such
as accelerometers, calls, short message service (SMS), social network data, or geolocation. In other
words, it is now possible to infer and collect behavioural information without necessarily asking the
person to report it.
Even though they were not investigated in the studies targeted at MDD patients discussed here,
several opportunities can be found in the integration of EMA and EMI platforms with behavioural and
physiological signal processing, further mediated by machine learning algorithms. On the one hand,
several behavioural signals are readily collectable with the use of smartphone sensors, even though
they may lack the required specificity for mood recognition and prediction, as found by the Mobylize!
study [61]. On the other hand, due to recent advancements in sensor technologies, physiological
signals can be nowadays recorded unobtrusively by means of, for example, smartwatches and chest
bands. These could provide an EMA and/or EMI platform with additional markers that more closely
correlate to a person’s affective state, and that can be used as input to the analysis performed [61].
Consistently, models can be automatically learned that continuously estimate the patient’s affective state
by extracting and analysing salient features of physiological signals [86]. For instance, electrodermal
activity (EDA) and heart rate variability (HRV) have been extensively investigated as correlates of
users’ affective state, and they are considered non-invasive. They do not involve recording sensitive
information (as opposed to, for example, cameras and acoustic signals), and associated sensors do not
interfere with users’ daily routines. Consistently, patient-specific models can be automatically learned
that continuously estimate the patient’s affective state by extracting and analysing salient features of
physiological signals [86].
Unfortunately, the relation between physiological signals and affective states is not trivial and
mixed results are discussed in the literature [87]. Building on recent advances of machine learning,
recent studies obtained promising results by means of model personalisation for stress recognition [88]
and deep learning for mood prediction [89] using a combination of behavioural and physiological
markers in non-clinical populations. If thoroughly tested and consolidated through experimental
validations in EMA settings, a model of this type could provide a finer-grained description of the
evolution of the patient’s disorder throughout a long-term study, compared to surveys that are usually
filled in just a few times a day. It can be considered less obstructive to the patient’s life because
physiological data are recorded passively and do not require extra effort from the patient. Furthermore,
in EMI settings, if the recognition algorithm detects that the patient is in a critical state, it can
automatically trigger an intervention module associated with the platform or open a communication
channel between the patient and his/her therapist. Alternatively, predictive models that combine
information from physiological and behavioural signals to estimate the patient’s future mood, stress
level, and self-reported health (one or a few days in advance) can be automatically inferred [89]. After
identifying a risk threshold, these models would make it possible to plan interventions (or involve the
therapist) in advance, that is, before the patient’s affective state reaches a critical state.
We should, however, recognize that the use of EMAs and EMIs has some limitations. These
approaches are time-consuming and may be perceived as invasive by users. Patients are required to
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complete multiple assessments throughout a day, and protocols often last weeks. Moreover, people
might not be willing to share personal information. Finally, in terms of more ecological validity,
they may be advantageous for clinical purposes, but disadvantageous for research aims, because
they imply less experimental control. Because the data are collected during everyday life and in
naturalistic environments, it becomes hard or even impossible to have complete control over the
setting, and, therefore, it is not possible to rule out the role of confounding variables. Nevertheless,
due to the implementation of novel statistical procedures, a balance between research necessities and
clinical utility could be achieved [90]. If this were the case in the near future, EMAs and EMIs would
undoubtedly transform the field of mental health, greatly contributing to the bridging of science and
practice [91,92].
Overall, this systematic review clearly shows the emergence of ecological assessment and
intervention as a promising avenue for clinical psychology. The focus of the review was limited
to a specific clinical population. Still, promising results have been already shown also regarding
the application of EMA and EMI to anxiety disorders [93,94] and stress-related disorders [95,96],
highlighting the potential of these tools to provide psychological support in daily life and to investigate
symptom fluctuations across time. However, similar limitations and burning issues were also evidenced,
including the need for more high-quality trials, the gap between the clinical and research field, and the
importance of making EMAs and EMIs as engaging and tailored as possible. Altogether, there is
evidence showing the feasibility and preliminary efficacy of these approaches, but much more research
should be conducted before drawing definite conclusions.
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